<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462016000100031</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2015.11.007</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease]]></article-title>
<article-title xml:lang="es"><![CDATA[Avances recientes en los factores de riesgo, diagnóstico y tratamiento de la enfermedad linfoproliferativa post trasplante con infección por virus de Epstein-Barr]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguayo-Hiraldo]]></surname>
<given-names><![CDATA[Paibel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arasaratnam]]></surname>
<given-names><![CDATA[Reuben]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rouce]]></surname>
<given-names><![CDATA[Rayne H.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Baylor College of Medicine Texas Children's Cancer and Hematology Centers ]]></institution>
<addr-line><![CDATA[Houston Texas]]></addr-line>
<country>USA</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Baylor College of Medicine Center for Cell and Gene Therapy ]]></institution>
<addr-line><![CDATA[Houston Texas]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2016</year>
</pub-date>
<volume>73</volume>
<numero>1</numero>
<fpage>31</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462016000100031&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462016000100031&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462016000100031&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Fifty years after the first reports of Epstein-Barr virus (EBV)-associated endemic Burkitt's lymphoma, EBV has emerged as the third most prevalent oncogenic virus worldwide. EBV infection is associated with various malignancies including Hodgkin and non-Hodgkin lymphoma, NK/T-cell lymphoma and nasopharyngeal carcinoma. Despite the highly specific immunologic control in the immunocompetent host, EBV can cause severe complications in the immunocompromised host (namely, post-transplant lymphoproliferative disease). This is particularly a problem in patients with delayed immune reconstitution post-hematopoietic stem cell transplant or solid organ transplant. Despite advances in diagnostic techniques and treatment algorithms allowing earlier identification and treatment of patients at highest risk, mortality rates remain as high as 90% if not treated early. The cornerstones of treatment include reduction in immunosuppression and in vivo B cell depletion with an anti-CD20 monoclonal antibody. However, these treatment modalities are not always feasible due to graft rejection, emergence of graft vs. host disease, and toxicity. Newer treatment modalities include the use of adoptive T cell therapy, which has shown promising results in various EBV-related malignancies. In this article we will review recent advances in risk factors, diagnosis and management of EBV-associated malignancies, particularly post-transplant lymphoproliferative disease. We will also discuss new and innovative treatment options including adoptive T cell therapy as well as management of special situations such as chronic active EBV and EBV-associated hemophagocytic lymphohistiocytosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[A cincuenta años de los primeros reportes de asociación del linfoma de Burkitt con el virus de Epstein-Barr (VEB), el VEB ha emergido como el tercer virus de tipo oncogénico con mayor prevalencia a escala mundial. La infección por VEB se asocia con diversas neoplasias, incluyendo el linfoma de Hodgkin y el no Hodgkin, linfoma de células T/NK y carcinoma nasofaríngeo. A pesar del control inmunológico altamente específico en el huésped inmunocompetente, el VEB puede ocasionar complicaciones severas en el huésped inmunocomprometido (es decir, la enfermedad linfoproliferativa post-trasplante). Esto es un problema particularmente en pacientes en quienes se retrasa la reconstitución de la inmunidad después de un trasplante de células madre hematopoyéticas o un trasplante de órganos sólidos. A pesar de los avances en las técnicas de diagnóstico y los algoritmos de tratamiento que permiten la identificación temprana y el tratamiento de pacientes de alto riesgo, las tasas mortalidad siguen siendo muy altas (del 90%) si no se recibe tratamiento temprano. La piedra angular del tratamiento incluye la disminución de la inmunosupresión y la depleción de células B in vivo con un anticuerpo monoclonal anti-CD20. Sin embargo, estas modalidades de tratamiento no son siempre posibles debido al rechazo del injerto, la enfermedad de injerto contra huésped y la toxicidad. Nuevas modalidades de tratamiento incluyen el uso de la terapia adoptiva de células T, que ha mostrado resultados promisorios en diversas neoplasias relacionadas con el VEB. En este artículo se revisan los avances más recientes en cuanto a los factores de riesgo, diagnóstico y tratamiento de las neoplasias asociadas con VEB, particularmente la enfermedad linfoproliferativa post-trasplante. También se discuten los tratamientos más recientes e innovadores, que incluyen la terapia adoptiva de células T así como el manejo de situaciones especiales, como la infección crónica activa de VEB y la linfohistiocitosis hemafagocítica asociada con VEB.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Virus de Epstein-Barr]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad linfoproliferativa post-trasplante]]></kwd>
<kwd lng="es"><![CDATA[Inmunoterapia]]></kwd>
<kwd lng="es"><![CDATA[Trasplante de células madre hematopoyéticas]]></kwd>
<kwd lng="es"><![CDATA[Trasplante de órgano sólido]]></kwd>
<kwd lng="en"><![CDATA[Epstein-Barr virus]]></kwd>
<kwd lng="en"><![CDATA[Post-transplant lymphoproliferative disease]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[Hematopoietic stem cell transplant]]></kwd>
<kwd lng="en"><![CDATA[Solid organ transplant]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adoptive therapy for EBV-induced cancers driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
</name>
</person-group>
<source><![CDATA[Immunotherapy]]></source>
<year>2015</year>
<volume>7</volume>
<page-range>563-72</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The role of Epstein-Barr virus in epithelial malignancies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsao]]></surname>
<given-names><![CDATA[S.W]]></given-names>
</name>
<name>
<surname><![CDATA[Tsang]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[To]]></surname>
<given-names><![CDATA[K.F]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[K.W]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pathol]]></source>
<year>2015</year>
<volume>235</volume>
<page-range>323-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[How I treat EBV lymphoproliferation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heslop]]></surname>
<given-names><![CDATA[H.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>114</volume>
<page-range>4002-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EBV and HIV-related lymphoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bibas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Antinori]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Mediterr J Hematol Infect Dis]]></source>
<year>2009</year>
<volume>1</volume>
<page-range>e2009032</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EBV-positive T/NK-cell lymphoproliferative disease of childhood]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[Y.H]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[K.H]]></given-names>
</name>
<name>
<surname><![CDATA[Koo]]></surname>
<given-names><![CDATA[H.H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S.J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[W.S]]></given-names>
</name>
</person-group>
<source><![CDATA[Korean J Pathol]]></source>
<year>2013</year>
<volume>47</volume>
<page-range>137-47</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uhlin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wikell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sundin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blennow]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maeurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ringden]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Haematologica]]></source>
<year>2014</year>
<volume>99</volume>
<page-range>346-52</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Three different histological subtypes of Epstein-Barr virus-negative post-transplant lymphoproliferative disorder in a patient with hepatitis C infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fukushima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Honda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Hematol]]></source>
<year>2014</year>
<volume>100</volume>
<page-range>307-11</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hashim]]></surname>
<given-names><![CDATA[M.H]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Agent Cancer]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swerdlow]]></surname>
<given-names><![CDATA[S.H]]></given-names>
</name>
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[N.L]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[E.S]]></given-names>
</name>
<name>
<surname><![CDATA[Pileri]]></surname>
<given-names><![CDATA[S.A]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[World Health Organization classification of tumors of haematopoietic and lymphoid tissues]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Lyon ]]></publisher-loc>
<publisher-name><![CDATA[International Agency for Research and Cancer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EBV-induced post-transplant lymphoproliferative disorders a persisting challenge in allogeneic hematopoetic SCT]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasche]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kapp]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Einsele]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mielke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Bone Marrow Transplantation]]></source>
<year>2014</year>
<volume>49</volume>
<page-range>163-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landgren]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[E.S]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[J.D]]></given-names>
</name>
<name>
<surname><![CDATA[Socié]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Banks]]></surname>
<given-names><![CDATA[P.M]]></given-names>
</name>
<name>
<surname><![CDATA[Sobocinski]]></surname>
<given-names><![CDATA[K.A]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>113</volume>
<page-range>4992-5001</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation-a case study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wróblewska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[L.A]]></given-names>
</name>
<name>
<surname><![CDATA[Komarnicki]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
</person-group>
<source><![CDATA[Cent Eur J Immunol]]></source>
<year>2015</year>
<volume>40</volume>
<page-range>122-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<source><![CDATA[European Conference on Infections in Leukemia]]></source>
<year>2011</year>
<volume>4</volume>
<publisher-name><![CDATA[ECIL]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rouce]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[C.U]]></given-names>
</name>
<name>
<surname><![CDATA[Heslop]]></surname>
<given-names><![CDATA[H.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Hematol]]></source>
<year>2014</year>
<volume>21</volume>
<page-range>476-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Styczynski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tridello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ljungman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[J.P]]></given-names>
</name>
<name>
<surname><![CDATA[van der Velden]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2013</year>
<volume>57</volume>
<page-range>794-802</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epstein-Barr virus infections in children after transplantation of the small intestine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finn]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yunis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>1998</year>
<volume>22</volume>
<page-range>299-309</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pediatric Heart Transplant Study. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chinnock]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Webber]]></surname>
<given-names><![CDATA[S.A]]></given-names>
</name>
<name>
<surname><![CDATA[Dipchand]]></surname>
<given-names><![CDATA[A.I]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[R.N]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[J.F]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Transplant]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>3061-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sokal]]></surname>
<given-names><![CDATA[E.M]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Beguin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bodeus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wallemacq]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[de Ville de Goyet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Transplantation]]></source>
<year>1997</year>
<volume>64</volume>
<page-range>1438-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2012 Annual Data Report of the U S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2000-2010. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation]]></article-title>
<collab>United States Organ Transplantation</collab>
<source><![CDATA[Am J Transplant]]></source>
<year>2014</year>
<volume>14</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>8-183</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xuan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hematol]]></source>
<year>2013</year>
<volume>88</volume>
<page-range>550-5</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinho-Apezzato]]></surname>
<given-names><![CDATA[M.L]]></given-names>
</name>
<name>
<surname><![CDATA[Tannuri]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Tannuri]]></surname>
<given-names><![CDATA[A.C]]></given-names>
</name>
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[E.S]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gibelli]]></surname>
<given-names><![CDATA[N.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Transplant Proc]]></source>
<year>2010</year>
<volume>42</volume>
<page-range>1763-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prompt versus preemptive intervention for EBV lymphoproliferative disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[H.J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Y.C]]></given-names>
</name>
<name>
<surname><![CDATA[Huls]]></surname>
<given-names><![CDATA[M.H]]></given-names>
</name>
<name>
<surname><![CDATA[Gee]]></surname>
<given-names><![CDATA[A.P]]></given-names>
</name>
<name>
<surname><![CDATA[Kuehnle]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Krance]]></surname>
<given-names><![CDATA[R.A]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2004</year>
<volume>103</volume>
<page-range>3979-81</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ESGICH PTLD Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID). Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[San-Juan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Manuel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[H.H]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Ruiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López-Medrano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Comoli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>604e1-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrara]]></surname>
<given-names><![CDATA[M.R]]></given-names>
</name>
<name>
<surname><![CDATA[Giunco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Serraino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dolcetti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Rossi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Lett]]></source>
<year>2015</year>
<volume>369</volume>
<page-range>37-44</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections and Leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Styczynski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Reusser]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Einsele]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de la Camara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[K.N]]></given-names>
</name>
</person-group>
<source><![CDATA[Bone Marrow Transplant]]></source>
<year>2009</year>
<volume>43</volume>
<page-range>757-70</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[G Low-dose chemotherapy for children with post-transplant lymphoproliferative disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Recent Results Cancer Res]]></source>
<year>2002</year>
<volume>159</volume>
<page-range>96-103</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): a Children&amp;apos;s Oncology Gr**oup Report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[T.G]]></given-names>
</name>
<name>
<surname><![CDATA[Orjuela]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[S.L]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J.R]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[J.C]]></given-names>
</name>
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[M.S]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Transplant]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>3069-75</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Cadenas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barba]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Esquirol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Novelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Bone Marrow Transplant]]></source>
<year>2015</year>
<volume>50</volume>
<page-range>579-84</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[T-cell therapy in the treatment of post-transplant lymphoproliferative disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollard]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Rooney]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Heslop]]></surname>
<given-names><![CDATA[H.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2012</year>
<volume>9</volume>
<page-range>510-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Outcome of treatment of Epstein-Barr virus related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients a comprehensive review of reported cases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Styczynski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Einsele]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liungman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Transpl Infect Dis]]></source>
<year>2009</year>
<volume>11</volume>
<page-range>383-92</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doubrovina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oflaz-Sozmen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Prockop]]></surname>
<given-names><![CDATA[S.E]]></given-names>
</name>
<name>
<surname><![CDATA[Kernan]]></surname>
<given-names><![CDATA[N.A]]></given-names>
</name>
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Teruya-Feldstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<page-range>2644-56</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollard]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Gottschalk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Torrano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Diouf]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ku]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hazrat]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>798-808</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Icheva]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kayser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tuve]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kyzirakos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bethge]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>39-48</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerdemann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Katari]]></surname>
<given-names><![CDATA[U.L]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Keirnan]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Craddock]]></surname>
<given-names><![CDATA[J.A]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>2113-21</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerdemann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Keirnan]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Katari]]></surname>
<given-names><![CDATA[U.L]]></given-names>
</name>
<name>
<surname><![CDATA[Yanagisawa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Christin]]></surname>
<given-names><![CDATA[A.S]]></given-names>
</name>
<name>
<surname><![CDATA[Huye]]></surname>
<given-names><![CDATA[L.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2012</year>
<volume>20</volume>
<page-range>1622-32</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV and HHV6 infections after HSCT]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papadopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gerdemann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Katari]]></surname>
<given-names><![CDATA[U.L]]></given-names>
</name>
<name>
<surname><![CDATA[Tzannou]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Sci Transl Med]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>242ra83</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leen]]></surname>
<given-names><![CDATA[A.M]]></given-names>
</name>
<name>
<surname><![CDATA[Bollard]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Mendizabal]]></surname>
<given-names><![CDATA[A.M]]></given-names>
</name>
<name>
<surname><![CDATA[Shpall]]></surname>
<given-names><![CDATA[E.J]]></given-names>
</name>
<name>
<surname><![CDATA[Szabolcs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antin]]></surname>
<given-names><![CDATA[J.H]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>121</volume>
<page-range>5113-23</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savoldo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goss]]></surname>
<given-names><![CDATA[J.A]]></given-names>
</name>
<name>
<surname><![CDATA[Hammer]]></surname>
<given-names><![CDATA[M.M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gee]]></surname>
<given-names><![CDATA[A.P]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<page-range>2942-9</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haque]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkie]]></surname>
<given-names><![CDATA[G.M]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[M.M]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[C.D]]></given-names>
</name>
<name>
<surname><![CDATA[Urquhart]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wingate]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>1123-31</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systemic inflammatory response syndrome after administration of unmodified T lymphocytes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papadopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Krance]]></surname>
<given-names><![CDATA[R.A]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C.E]]></given-names>
</name>
<name>
<surname><![CDATA[Rooney]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[M.K]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>1134-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Swerdlow]]></surname>
<given-names><![CDATA[S.H]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[N.L]]></given-names>
</name>
<name>
<surname><![CDATA[Pileri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[E.S]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>117</volume>
<page-range>5019-32</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[E Familial and aquired hemophagocytic lymphohistiocytosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janka]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Annu Rev Med]]></source>
<year>2012</year>
<volume>63</volume>
<page-range>233-46</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of rare co-ocurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohystiocytosis after allogeneic stem cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wickenhauser]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Monecke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gläser]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stadler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Desole]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ligeti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Transpl Infect Dis]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>988-92</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis a dreaded complication in a post-liver transplant child]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gajendra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sachdev]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sahni]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Transplant]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>177-80</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Initial hyperleukocytosis and neutrophilia in nasopharyngeal carcinoma: incidence and prognostic impact]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[Y.P]]></given-names>
</name>
<name>
<surname><![CDATA[OuYang]]></surname>
<given-names><![CDATA[P.Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[F.Y]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS ONE]]></source>
<year>2015</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Early life exposures to infectious agents and later cancer developement]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vedham]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mahabi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Med]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[National Comprehensive Cancer Network. Head and Neck Cancers, Version 1.2015]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfister]]></surname>
<given-names><![CDATA[D.G]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brizel]]></surname>
<given-names><![CDATA[D.M]]></given-names>
</name>
<name>
<surname><![CDATA[Burtness]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[P.M]]></given-names>
</name>
<name>
<surname><![CDATA[Caudell]]></surname>
<given-names><![CDATA[J.J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>847-55</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chia]]></surname>
<given-names><![CDATA[W.K]]></given-names>
</name>
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W.W]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ang]]></surname>
<given-names><![CDATA[S.F]]></given-names>
</name>
<name>
<surname><![CDATA[Tai]]></surname>
<given-names><![CDATA[W.M]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>132-9</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comoli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrazzoli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maccario]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carminati]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Labirio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>8942-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[C.U]]></given-names>
</name>
<name>
<surname><![CDATA[Straathof]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bollard]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Ennamuri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gerken]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[T.T]]></given-names>
</name>
</person-group>
<source><![CDATA[J Immunother]]></source>
<year>2010</year>
<volume>33</volume>
<page-range>983-90</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Targeting EBV&amp;apos;s Achilles' heel with antigen-specific T cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gottschalk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunotherapy]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>353-5</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gottschalk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leen]]></surname>
<given-names><![CDATA[A.M]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Straarhof]]></surname>
<given-names><![CDATA[K.C]]></given-names>
</name>
<name>
<surname><![CDATA[Carrum]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>2838-45</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[S.G]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[H.J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S.K]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[S.T]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H.J]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2015</year>
<volume>23</volume>
<page-range>1401-9</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of 2001 evidence-based review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliansky]]></surname>
<given-names><![CDATA[D.M]]></given-names>
</name>
<name>
<surname><![CDATA[Czuzman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[R.I]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[F.D]]></given-names>
</name>
<name>
<surname><![CDATA[Lazarus]]></surname>
<given-names><![CDATA[H.M]]></given-names>
</name>
<name>
<surname><![CDATA[Omel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>20-47</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lymphoma after solid organ transplantation: risk, response to therapy, and suvival at a transplantation center]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[J.S]]></given-names>
</name>
<name>
<surname><![CDATA[Tsodikov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cibrik]]></surname>
<given-names><![CDATA[D.M]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[C.W]]></given-names>
</name>
<name>
<surname><![CDATA[Kaminski]]></surname>
<given-names><![CDATA[M.S]]></given-names>
</name>
<name>
<surname><![CDATA[Blayney]]></surname>
<given-names><![CDATA[D.W]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2009</year>
<volume>27</volume>
<page-range>3354-62</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
